SPRYARS Pharmaceuticals, Inc.
Is it safe?
Caution warranted: heavy debt (BB) and big price swings.
Net cash, but unprofitable, speculative. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -95% · now 65% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can SPRY take a bad year?
ARS Pharmaceuticals, Inc. holds $47M more cash than debt, and is burning $49M a quarter, about 0.7 years of cover.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Cash runway
- 0.7 years
Cash runway · burning $49M a quarter at the current rate
- Annualised volatility
- 69%
Annualised volatility · three times the market's own swing
Details›
- Total debtQ2 2026
- $97M
- Cash and short-term investments
- $144M
- Net cash
- $47M
- EBITDA, trailing twelve months
- −$215M
- Operating profit, trailing twelve months
- −$216M
- Debt / equity
- 7.73×
- Annualised volatilitytwo years of daily moves
- 69%
- Worst drawdown on file
- −95%
- Below its 52-week high
- 65%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.